<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01520727</url>
  </required_header>
  <id_info>
    <org_study_id>BIA-91067-101</org_study_id>
    <nct_id>NCT01520727</nct_id>
  </id_info>
  <brief_title>A Single Oral Ascending Dose Study of BIA 9-1067 in Healthy Male Subjects</brief_title>
  <official_title>A Single Oral Ascending Dose Study to Investigate the Safety, Pharmacokinetics and Catechol-O-methyltransferase (COMT) Inhibition Profiles of BIA 9-1067 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bial - Portela C S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bial - Portela C S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to investigate the safety, tolerability, pharmacokinetics and
      catechol-O-methyltransferase (COMT) activity of BIA 9-1067 in healthy male subjects after
      single oral ascending doses.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Single centre, randomised, double-blind, placebo-controlled study of single ascending doses
      in up to 8 sequential groups of 8 healthy young male subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events (AEs)</measure>
    <time_frame>7 weeks</time_frame>
    <description>Safety was evaluated from the number of reported adverse events (AEs)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax - BIA 9-1067</measure>
    <time_frame>pre-dose then post-dose. Hour 0.25, 0.5, 0,75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48 , 60 and 72 hours post dose</time_frame>
    <description>Cmax - maximum plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Cmax (Tmax)</measure>
    <time_frame>pre-dose then post-dose. Hour 0.25, 0.5, 0,75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48 , 60 and 72 hours post dose</time_frame>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>BIA 9-1067 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BIA 9-1067 (Opicapone, OPC) - 10 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BIA 9-1067 25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BIA 9-1067 (Opicapone, OPC) - 25 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BIA 9-1067 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BIA 9-1067 (Opicapone, OPC) - 50 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BIA 9-1067 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BIA 9-1067 (Opicapone, OPC) - 100 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BIA 9-1067 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BIA 9-1067 (Opicapone, OPC) - 200 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BIA 9-1067 400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BIA 9-1067 (Opicapone, OPC) - 400 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BIA 9-1067 800 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BIA 9-1067 (Opicapone, OPC) - 800 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BIA 9-1067 1200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BIA 9-1067 (Opicapone, OPC) - 1200 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (PLC): single-dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIA 9-1067</intervention_name>
    <description>single ascending doses in up to 8 sequential groups of 8 healthy young male subjects</description>
    <arm_group_label>BIA 9-1067 10 mg</arm_group_label>
    <arm_group_label>BIA 9-1067 25 mg</arm_group_label>
    <arm_group_label>BIA 9-1067 50 mg</arm_group_label>
    <arm_group_label>BIA 9-1067 100 mg</arm_group_label>
    <arm_group_label>BIA 9-1067 200 mg</arm_group_label>
    <arm_group_label>BIA 9-1067 400 mg</arm_group_label>
    <arm_group_label>BIA 9-1067 800 mg</arm_group_label>
    <arm_group_label>BIA 9-1067 1200 mg</arm_group_label>
    <other_name>Entacapone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>single-dose</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A signed and dated informed consent form before any study-specific screening procedure
             was performed.

          -  Aged between 18 and 45 years, inclusive.

          -  Healthy as determined by the investigator on the basis of medical history, physical
             examination, clinical laboratory test results, vital signs and digital 12-lead ECG.

          -  Non-smoker or smoker of fewer than 10 cigarettes per day as determined by history.
             Must be able to abstain from smoking during the inpatient stay.

        Exclusion Criteria:

          -  Any significant cardiovascular (e.g. hypertension), hepatic, renal, respiratory (e.g.
             childhood asthma), gastrointestinal, endocrine (e.g. diabetes, dyslipidemia),
             immunologic, dermatological, haematological, neurologic, or psychiatric disease.

          -  Acute disease state (e.g., nausea, vomiting, fever, diarrhoea) within 7 days before
             study day 1.

          -  History of drug abuse within 1 year before study day 1.

          -  History of alcoholism within 1 year before day 1. Consumption of more than 50 g of
             ethanol per day (12.5 cL glass of 10° [10%] wine = 12 g; 4 cL of aperitif, 42° [42%]
             whiskey = 17 g; 25 cL glass of 3° [3%] beer = 7.5 g; 25 cL glass of 6° [6%] beer = 15
             g

          -  Positive serologic findings for human immunodeficiency virus (HIV) antibodies,
             hepatitis B surface antigen (HBsAg), and/or hepatitis C virus (HCV) antibodies.

          -  Positive findings of urine drug screen (eg, amphetamines, barbiturates,
             benzodiazepines, cannabinoids, cocaine, methadone, opiates, MDMA
             [3,4-methylenedioxy-methamphetamine; ecstasy]).

          -  History of any clinically important drug allergy.

          -  Prohibited Treatments: use of any investigational drug within 90 days or prescription
             drug within 30 days before investigational medical product (IMP) administration.

          -  Consumption of any caffeine-containing products (e.g., coffee, tea, chocolate, or
             soda) in excess of 6 cups per day (or equivalent), of grapefruit,
             grapefruit-containing products, or alcoholic beverages within 24 hours before study
             day 1.

          -  Use of any over-the-counter drugs including herbal supplements (except for the
             occasional use of acetaminophen [paracetamol], aspirin and vitamins ≤100% recommended
             daily allowance) within 7 days before IMP administration.

          -  Donation of blood (i.e. 450 mL) within 60 days before study day 1
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolas Fauchoux, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>BIOTRIAL</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>BIOTRIAL</name>
      <address>
        <city>Rennes</city>
        <zip>F-35000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 18, 2012</study_first_submitted>
  <study_first_submitted_qc>January 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2012</study_first_posted>
  <results_first_submitted>December 29, 2014</results_first_submitted>
  <results_first_submitted_qc>December 29, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 8, 2015</results_first_posted>
  <last_update_submitted>December 29, 2014</last_update_submitted>
  <last_update_submitted_qc>December 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BIA 9-1067</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opicapone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>BIA 9-1067 10 mg</title>
          <description>BIA 9-1067 (Opicapone, OPC) - 10 mg
BIA 9-1067: single ascending doses in up to 8 sequential groups of 8 healthy young male subjects</description>
        </group>
        <group group_id="P2">
          <title>BIA 9-1067 25 mg</title>
          <description>BIA 9-1067 (Opicapone, OPC) - 25 mg
BIA 9-1067: single ascending doses in up to 8 sequential groups of 8 healthy young male subjects</description>
        </group>
        <group group_id="P3">
          <title>BIA 9-1067 50 mg</title>
          <description>BIA 9-1067 (Opicapone, OPC) - 50 mg
BIA 9-1067: single ascending doses in up to 8 sequential groups of 8 healthy young male subjects</description>
        </group>
        <group group_id="P4">
          <title>BIA 9-1067 100 mg</title>
          <description>BIA 9-1067 (Opicapone, OPC) - 100 mg
BIA 9-1067: single ascending doses in up to 8 sequential groups of 8 healthy young male subjects</description>
        </group>
        <group group_id="P5">
          <title>BIA 9-1067 200 mg</title>
          <description>BIA 9-1067 (Opicapone, OPC) - 200 mg
BIA 9-1067: single ascending doses in up to 8 sequential groups of 8 healthy young male subjects</description>
        </group>
        <group group_id="P6">
          <title>BIA 9-1067 400 mg</title>
          <description>BIA 9-1067 (Opicapone, OPC) - 400 mg
BIA 9-1067: single ascending doses in up to 8 sequential groups of 8 healthy young male subjects</description>
        </group>
        <group group_id="P7">
          <title>BIA 9-1067 800 mg</title>
          <description>BIA 9-1067 (Opicapone, OPC) - 800 mg
BIA 9-1067: single ascending doses in up to 8 sequential groups of 8 healthy young male subjects</description>
        </group>
        <group group_id="P8">
          <title>BIA 9-1067 1200 mg</title>
          <description>BIA 9-1067 (Opicapone, OPC) - 1200 mg
BIA 9-1067: single ascending doses in up to 8 sequential groups of 8 healthy young male subjects</description>
        </group>
        <group group_id="P9">
          <title>Placebo</title>
          <description>Placebo (PLC): single-dose
Placebo: single-dose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>BIA 9-1067 10 mg</title>
          <description>BIA 9-1067 (Opicapone, OPC) - 10 mg
BIA 9-1067: single ascending doses in up to 8 sequential groups of 8 healthy young male subjects</description>
        </group>
        <group group_id="B2">
          <title>BIA 9-1067 25 mg</title>
          <description>BIA 9-1067 (Opicapone, OPC) - 25 mg
BIA 9-1067: single ascending doses in up to 8 sequential groups of 8 healthy young male subjects</description>
        </group>
        <group group_id="B3">
          <title>BIA 9-1067 50 mg</title>
          <description>BIA 9-1067 (Opicapone, OPC) - 50 mg
BIA 9-1067: single ascending doses in up to 8 sequential groups of 8 healthy young male subjects</description>
        </group>
        <group group_id="B4">
          <title>BIA 9-1067 100 mg</title>
          <description>BIA 9-1067 (Opicapone, OPC) - 100 mg
BIA 9-1067: single ascending doses in up to 8 sequential groups of 8 healthy young male subjects</description>
        </group>
        <group group_id="B5">
          <title>BIA 9-1067 200 mg</title>
          <description>BIA 9-1067 (Opicapone, OPC) - 200 mg
BIA 9-1067: single ascending doses in up to 8 sequential groups of 8 healthy young male subjects</description>
        </group>
        <group group_id="B6">
          <title>BIA 9-1067 400 mg</title>
          <description>BIA 9-1067 (Opicapone, OPC) - 400 mg
BIA 9-1067: single ascending doses in up to 8 sequential groups of 8 healthy young male subjects</description>
        </group>
        <group group_id="B7">
          <title>BIA 9-1067 800 mg</title>
          <description>BIA 9-1067 (Opicapone, OPC) - 800 mg
BIA 9-1067: single ascending doses in up to 8 sequential groups of 8 healthy young male subjects</description>
        </group>
        <group group_id="B8">
          <title>BIA 9-1067 1200 mg</title>
          <description>BIA 9-1067 (Opicapone, OPC) - 1200 mg
BIA 9-1067: single ascending doses in up to 8 sequential groups of 8 healthy young male subjects</description>
        </group>
        <group group_id="B9">
          <title>Placebo</title>
          <description>Placebo (PLC): single-dose
Placebo: single-dose</description>
        </group>
        <group group_id="B10">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="6"/>
            <count group_id="B8" value="6"/>
            <count group_id="B9" value="16"/>
            <count group_id="B10" value="64"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="16"/>
                    <measurement group_id="B10" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="16"/>
                    <measurement group_id="B10" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Adverse Events (AEs)</title>
        <description>Safety was evaluated from the number of reported adverse events (AEs)</description>
        <time_frame>7 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BIA 9-1067 10 mg</title>
            <description>BIA 9-1067 (Opicapone, OPC) - 10 mg
BIA 9-1067: single ascending doses in up to 8 sequential groups of 8 healthy young male subjects</description>
          </group>
          <group group_id="O2">
            <title>BIA 9-1067 25 mg</title>
            <description>BIA 9-1067 (Opicapone, OPC) - 25 mg
BIA 9-1067: single ascending doses in up to 8 sequential groups of 8 healthy young male subjects</description>
          </group>
          <group group_id="O3">
            <title>BIA 9-1067 50 mg</title>
            <description>BIA 9-1067 (Opicapone, OPC) - 50 mg
BIA 9-1067: single ascending doses in up to 8 sequential groups of 8 healthy young male subjects</description>
          </group>
          <group group_id="O4">
            <title>BIA 9-1067 100 mg</title>
            <description>BIA 9-1067 (Opicapone, OPC) - 100 mg
BIA 9-1067: single ascending doses in up to 8 sequential groups of 8 healthy young male subjects</description>
          </group>
          <group group_id="O5">
            <title>BIA 9-1067 200 mg</title>
            <description>BIA 9-1067 (Opicapone, OPC) - 200 mg
BIA 9-1067: single ascending doses in up to 8 sequential groups of 8 healthy young male subjects</description>
          </group>
          <group group_id="O6">
            <title>BIA 9-1067 400 mg</title>
            <description>BIA 9-1067 (Opicapone, OPC) - 400 mg
BIA 9-1067: single ascending doses in up to 8 sequential groups of 8 healthy young male subjects</description>
          </group>
          <group group_id="O7">
            <title>BIA 9-1067 800 mg</title>
            <description>BIA 9-1067 (Opicapone, OPC) - 800 mg
BIA 9-1067: single ascending doses in up to 8 sequential groups of 8 healthy young male subjects</description>
          </group>
          <group group_id="O8">
            <title>BIA 9-1067 1200 mg</title>
            <description>BIA 9-1067 (Opicapone, OPC) - 1200 mg
BIA 9-1067: single ascending doses in up to 8 sequential groups of 8 healthy young male subjects</description>
          </group>
          <group group_id="O9">
            <title>Placebo</title>
            <description>Placebo (PLC): single-dose
Placebo: single-dose</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events (AEs)</title>
          <description>Safety was evaluated from the number of reported adverse events (AEs)</description>
          <units>Number of Adverse Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax - BIA 9-1067</title>
        <description>Cmax - maximum plasma concentration</description>
        <time_frame>pre-dose then post-dose. Hour 0.25, 0.5, 0,75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48 , 60 and 72 hours post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BIA 9-1067 10 mg</title>
            <description>BIA 9-1067 (Opicapone, OPC) - 10 mg
BIA 9-1067: single ascending doses in up to 8 sequential groups of 8 healthy young male subjects</description>
          </group>
          <group group_id="O2">
            <title>BIA 9-1067 25 mg</title>
            <description>BIA 9-1067 (Opicapone, OPC) - 25 mg
BIA 9-1067: single ascending doses in up to 8 sequential groups of 8 healthy young male subjects</description>
          </group>
          <group group_id="O3">
            <title>BIA 9-1067 50 mg</title>
            <description>BIA 9-1067 (Opicapone, OPC) - 50 mg
BIA 9-1067: single ascending doses in up to 8 sequential groups of 8 healthy young male subjects</description>
          </group>
          <group group_id="O4">
            <title>BIA 9-1067 100 mg</title>
            <description>BIA 9-1067 (Opicapone, OPC) - 100 mg
BIA 9-1067: single ascending doses in up to 8 sequential groups of 8 healthy young male subjects</description>
          </group>
          <group group_id="O5">
            <title>BIA 9-1067 200 mg</title>
            <description>BIA 9-1067 (Opicapone, OPC) - 200 mg
BIA 9-1067: single ascending doses in up to 8 sequential groups of 8 healthy young male subjects</description>
          </group>
          <group group_id="O6">
            <title>BIA 9-1067 400 mg</title>
            <description>BIA 9-1067 (Opicapone, OPC) - 400 mg
BIA 9-1067: single ascending doses in up to 8 sequential groups of 8 healthy young male subjects</description>
          </group>
          <group group_id="O7">
            <title>BIA 9-1067 800 mg</title>
            <description>BIA 9-1067 (Opicapone, OPC) - 800 mg
BIA 9-1067: single ascending doses in up to 8 sequential groups of 8 healthy young male subjects</description>
          </group>
          <group group_id="O8">
            <title>BIA 9-1067 1200 mg</title>
            <description>BIA 9-1067 (Opicapone, OPC) - 1200 mg
BIA 9-1067: single ascending doses in up to 8 sequential groups of 8 healthy young male subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax - BIA 9-1067</title>
          <description>Cmax - maximum plasma concentration</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130.7" spread="68.0"/>
                    <measurement group_id="O2" value="308.5" spread="128.1"/>
                    <measurement group_id="O3" value="522.2" spread="186.7"/>
                    <measurement group_id="O4" value="927.2" spread="378.9"/>
                    <measurement group_id="O5" value="1287.5" spread="585.6"/>
                    <measurement group_id="O6" value="2013.3" spread="608.7"/>
                    <measurement group_id="O7" value="2786.7" spread="1335.9"/>
                    <measurement group_id="O8" value="4883.3" spread="1501.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Cmax (Tmax)</title>
        <time_frame>pre-dose then post-dose. Hour 0.25, 0.5, 0,75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48 , 60 and 72 hours post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BIA 9-1067 10 mg</title>
            <description>BIA 9-1067 (Opicapone, OPC) - 10 mg
BIA 9-1067: single ascending doses in up to 8 sequential groups of 8 healthy young male subjects</description>
          </group>
          <group group_id="O2">
            <title>BIA 9-1067 25 mg</title>
            <description>BIA 9-1067 (Opicapone, OPC) - 25 mg
BIA 9-1067: single ascending doses in up to 8 sequential groups of 8 healthy young male subjects</description>
          </group>
          <group group_id="O3">
            <title>BIA 9-1067 50 mg</title>
            <description>BIA 9-1067 (Opicapone, OPC) - 50 mg
BIA 9-1067: single ascending doses in up to 8 sequential groups of 8 healthy young male subjects</description>
          </group>
          <group group_id="O4">
            <title>BIA 9-1067 100 mg</title>
            <description>BIA 9-1067 (Opicapone, OPC) - 100 mg
BIA 9-1067: single ascending doses in up to 8 sequential groups of 8 healthy young male subjects</description>
          </group>
          <group group_id="O5">
            <title>BIA 9-1067 200 mg</title>
            <description>BIA 9-1067 (Opicapone, OPC) - 200 mg
BIA 9-1067: single ascending doses in up to 8 sequential groups of 8 healthy young male subjects</description>
          </group>
          <group group_id="O6">
            <title>BIA 9-1067 400 mg</title>
            <description>BIA 9-1067 (Opicapone, OPC) - 400 mg
BIA 9-1067: single ascending doses in up to 8 sequential groups of 8 healthy young male subjects</description>
          </group>
          <group group_id="O7">
            <title>BIA 9-1067 800 mg</title>
            <description>BIA 9-1067 (Opicapone, OPC) - 800 mg
BIA 9-1067: single ascending doses in up to 8 sequential groups of 8 healthy young male subjects</description>
          </group>
          <group group_id="O8">
            <title>BIA 9-1067 1200 mg</title>
            <description>BIA 9-1067 (Opicapone, OPC) - 1200 mg
BIA 9-1067: single ascending doses in up to 8 sequential groups of 8 healthy young male subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Cmax (Tmax)</title>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="2.0" upper_limit="4.0"/>
                    <measurement group_id="O2" value="1.5" lower_limit="1.0" upper_limit="4.0"/>
                    <measurement group_id="O3" value="3.5" lower_limit="1.5" upper_limit="4.0"/>
                    <measurement group_id="O4" value="1.8" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O5" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O6" value="2.0" lower_limit="1.5" upper_limit="5.0"/>
                    <measurement group_id="O7" value="2.5" lower_limit="0.8" upper_limit="5.3"/>
                    <measurement group_id="O8" value="1.5" lower_limit="1.0" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>BIA 9-1067 10 mg</title>
          <description>BIA 9-1067 (Opicapone, OPC) - 10 mg
BIA 9-1067: single ascending doses in up to 8 sequential groups of 8 healthy young male subjects</description>
        </group>
        <group group_id="E2">
          <title>BIA 9-1067 25 mg</title>
          <description>BIA 9-1067 (Opicapone, OPC) - 25 mg
BIA 9-1067: single ascending doses in up to 8 sequential groups of 8 healthy young male subjects</description>
        </group>
        <group group_id="E3">
          <title>BIA 9-1067 50 mg</title>
          <description>BIA 9-1067 (Opicapone, OPC) - 50 mg
BIA 9-1067: single ascending doses in up to 8 sequential groups of 8 healthy young male subjects</description>
        </group>
        <group group_id="E4">
          <title>BIA 9-1067 100 mg</title>
          <description>BIA 9-1067 (Opicapone, OPC) - 100 mg
BIA 9-1067: single ascending doses in up to 8 sequential groups of 8 healthy young male subjects</description>
        </group>
        <group group_id="E5">
          <title>BIA 9-1067 200 mg</title>
          <description>BIA 9-1067 (Opicapone, OPC) - 200 mg
BIA 9-1067: single ascending doses in up to 8 sequential groups of 8 healthy young male subjects</description>
        </group>
        <group group_id="E6">
          <title>BIA 9-1067 400 mg</title>
          <description>BIA 9-1067 (Opicapone, OPC) - 400 mg
BIA 9-1067: single ascending doses in up to 8 sequential groups of 8 healthy young male subjects</description>
        </group>
        <group group_id="E7">
          <title>BIA 9-1067 800 mg</title>
          <description>BIA 9-1067 (Opicapone, OPC) - 800 mg
BIA 9-1067: single ascending doses in up to 8 sequential groups of 8 healthy young male subjects</description>
        </group>
        <group group_id="E8">
          <title>BIA 9-1067 1200 mg</title>
          <description>BIA 9-1067 (Opicapone, OPC) - 1200 mg
BIA 9-1067: single ascending doses in up to 8 sequential groups of 8 healthy young male subjects</description>
        </group>
        <group group_id="E9">
          <title>Placebo</title>
          <description>Placebo (PLC): single-dose
Placebo: single-dose</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Spastic Paraplegia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope Vasovagal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Orthostatic Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Head of Clinical Research</name_or_title>
      <organization>Bial – Portela &amp; Cª, S.A.</organization>
      <phone>+351 229 866 100</phone>
      <email>jose.rocha@bial.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

